Skip to content.

Bio-IT World

On-Demand: White Papers
Visit our white paper library often
to understand more about key
technology issues in bio-IT today
Bio-IT World
Conference & Expo

April 30 - May 2, 2007
Register by March. 16th
& SAVE up to $200!
Personal tools
March 14, 2007 | Home > Health-IT > Business+Strategy >

Business+Strategy :: Finance & Markets

Schering-Plough Tries to Deal Its Way to Top
Mar 13 | The Wall Street Journal | After spending the past four years patiently nursing midsize drug maker Schering-Plough Corp. back to health, veteran pharmaceutical-industry executive Fred Hassan resumed doing what he loves most: making deals. more
Schering-Plough to Buy Akzo's Drug-Making Division for $14.4B
Mar 12 | Bloomberg.com | Schering-Plough Corp. agreed to buy Akzo Nobel NV's drug-making division Organon for $14.4 billion in cash to gain the world's third-largest maker of birth-control pills and a stable of experimental medicines. more
Novartis Rally Seen on Key U.S. Drug Approval
Mar 06 | Reuters | Swiss drug group Novartis has received its first U.S. approval for the potential blockbuster blood pressure drug Tekturna, in a move expected to spark a rally in Novartis shares. more
A Rock Star of Biotechs Plans IPO
Mar 06 | The Boston Globe | Sirtris Pharmaceuticals Inc. , a young Cambridge, Mass., biotechnology company trying to parlay life-extension research into drugs for diabetes and other metabolic problems, hopes to raise up to $60 million in an initial public offering. more
Glaxo Pipeline Dented as Mid-Stage Drugs Dropped
Mar 05 | Reuters | GlaxoSmithKline Plc's claim to have one of the best new drug pipelines in the industry has suffered a setback with the loss of a number of experimental medicines in mid-stage clinical testing. more
Gene Logic Says May Spin Off Genomics Division
Feb 26 | Reuters | Gene Logic Inc. on Friday said it may spin off its genomics business, while continuing to retain a stake in the struggling segment. more
FDA Delays Approval of Novartis Diabetes Drug
Feb 26 | The Wall Street Journal | Novartis AG said Monday that the FDA requested it to conduct an additional study on experimental diabetes drug Galvus before approving it, delaying by about a year the launch of one of the company's most important new products. more
Bio-IT Briefs
Mar 09 | Bio-IT World | FULL STORIES

  • Sigma-Aldrich launches Mission siRNA druggable genome libraries
  • InforSense unveils Customer Hub to empower life scientists and informaticians
  • BlueGnome updates its CytoChip with known copy number variations
  • NIH director launches funding program for innovative new investigators
  • Computer program predicts risk of breast cancer

 
Advertisement
Ads By Google
 
The CHI Network

For reprints and/or copyright permission, please contact RMS, 1808 Colonial Village Lane, Lancaster, PA; (717) 399-1900 ext 100 or via email to [email protected].

 

©2002-2007 Bio-IT World Inc. Privacy Policy | March 14, 2007